| Date Checked | 2026-04-21 04:57:54 |
|---|---|
| Graham Number | (PB)nan vs (PE)69.00 |
| Over / Under Value Percentage | 0.00% vs nan% |
| Dividend Yield | 3.22% |
| Dividend Date | 2026-05-15 |
| Symbol | ABBV |
| AssetType | Common Stock |
| Name | AbbVie Inc |
| Description | AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. |
| CIK | 1551152 |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, UNITED STATES, 60064-6400 |
| OfficialSite | https://www.abbvie.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-12-31 |
| MarketCapitalization | 374252438000 |
| EBITDA | 29254001000 |
| PERatio | 89.28 |
| PEGRatio | 0.495 |
| BookValue | -1.85 |
| DividendPerShare | 6.65 |
| EPS | 2.37 |
| RevenuePerShareTTM | 34.57 |
| ProfitMargin | 0.0691 |
| OperatingMarginTTM | 0.341 |
| ReturnOnAssetsTTM | 0.0981 |
| ReturnOnEquityTTM | 0.623 |
| RevenueTTM | 61160002000 |
| GrossProfitTTM | 43803001000 |
| DilutedEPSTTM | 2.37 |
| QuarterlyEarningsGrowthYOY | -0.887 |
| QuarterlyRevenueGrowthYOY | 0.1 |
| AnalystTargetPrice | 249.14 |
| AnalystRatingStrongBuy | 8 |
| AnalystRatingBuy | 14 |
| AnalystRatingHold | 9 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | 89.28 |
| ForwardPE | 14.35 |
| PriceToSalesRatioTTM | 6.12 |
| PriceToBookRatio | 50.46 |
| EVToRevenue | 7.06 |
| EVToEBITDA | 24.48 |
| Beta | 0.364 |
| 52WeekHigh | 241.12 |
| 52WeekLow | 163.83 |
| 50DayMovingAverage | 221.37 |
| 200DayMovingAverage | 216.27 |
| SharesOutstanding | 1768762000 |
| SharesFloat | 1765057000 |
| PercentInsiders | 0.117 |
| PercentInstitutions | 76.396 |
| ExDividendDate | 2026-04-15 |
| naga | 1 |
| etoro | 1 |
| dateChecked | 2026-04-21 04:57:54 |
| fresh | 1 |